Advertisement WellWorld Science Launches Livea In US - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

WellWorld Science Launches Livea In US

WellWorld Science has officially launched Livea, a doctor-developed, non-prescription, patent-pending appetite-control supplement, in the US.

The company said that Livea mimics the body’s natural signaling process making the body feel full, leading to weight loss. As the proprietary blend of ingredients is all-natural, it can be safely consumed for an extended period, unlike other products that can have long-term, adverse side effects after short-term use.

Joseph Fayad, gastroenterologist and expert on neuropeptide research, said: “Based on an independent, open-label weight loss study, Livea demonstrated that it safely and effectively helped patients consume fewer calories than those who did not take the supplement.

“These peptides, which Livea activates, are being studied in their role in treating fatty liver disease, improving various organ functions and treating diverse autoimmune disorders, including Type II Diabetes and Multiple Sclerosis.”

The company claims that the positive results of Livea and its Lifestyle Program go beyond the weight loss benefits. With current research showing a link between neuropeptide deficiency and many common health concerns, Livea appears to be promising in weight management.